Who is sponsoring NCT05744622?

NCT05744622 is sponsored by Suez Canal University.

What drugs are being tested in NCT05744622?

Interventions in NCT05744622: KetacTM Universal AplicapTM, KetacTM Universal AplicapTM with light cure.

What condition does NCT05744622 study?

NCT05744622 studies High Caries Risk Patients.

Is NCT05744622 still recruiting?

NCT05744622 is currently completed. Last updated 27 February 2023.

Last reviewed 2023-02-27 · How we verify

NCT05744622

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Clinical Evaluation of Chemically Cured Conventional Glass Ionomer After Light Emitting Diode Radiant Heat Enhancement

Completed NA Last updated 27 February 2023

What this trial tests

NA trial testing KetacTM Universal AplicapTM in High Caries Risk Patients in 18 participants. Completed in 22 May 2022.

Timeline

20 February 2021

Primary endpoint
20 February 2022

22 May 2022

Quick facts

Lead sponsor	Suez Canal University
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	triple
Primary purpose	treatment
Enrollment	18
Start date	20 February 2021
Primary completion	20 February 2022
Estimated completion	22 May 2022
Sites	1 location across Egypt

Drugs / interventions tested

KetacTM Universal AplicapTM
KetacTM Universal AplicapTM with light cure

Conditions studied

High Caries Risk Patients — all drugs for High Caries Risk Patients →

Sponsor

Suez Canal University

Who can join

Adults 21 to 45, any sex, with High Caries Risk Patients. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Introduction: Glass ionomer cements (GICs) are widely used in clinical dentistry due to their advantageous properties. However, they present inferior physical and mechanical properties compared to resin composites. Aim: Clinical evaluation of chemically cured conventional glass ionomer after light-emitting diode radiant heat enhancement. . Methodology: Eighteen healthy patients with 36-second molar teeth will be selected where each patient should have two oclusso- mesial cavities. Standardized oclusso- mesial cavities will be prepared for all the selected teeth, for each patient the first tooth will be restored with chemically cured conventional GICs without any enhancement (M1 group). Meanwhile, the second tooth will be restored by chemically cured conventional GICs that enhanced with radiant heat (LED) (M2 group). functional and biological criteria of each restoration will be clinically evaluated at 4 time points

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Clinical Evaluation of Chemically Cured Conventional Glass Ionomer after Light Emitting Diode Radiant Heat Enhancement: A Randomized Controlled Clinical Trial.
Ebrahim EA, Mohamed BH, Fahmy OMI, Safy RK. · · 2025 · PMID 40621145 · DOI 10.4317/jced.62440

Verify or expand the search:

Other Suez Canal University trials

Trials by the same sponsor.

NCT07263893 — Inter Flex Three Dimensional Plate in Management of Mandibular Fracture RCT · NA · recruiting
NCT07280533 — Accuracy of Virtual Surgical Planning Versus Traditional Technique in Zygomaticomaxillary Fracture Reduction · NA · not yet recruiting
NCT07291791 — tDCS for Pain Modulation in Knee Osteoarthritis · NA · active not recruiting
NCT07262086 — Clinical Evaluation of Wear Resistance and Bioactivity of Self Cured Bioactive Resin Composite · NA · enrolling by invitation
NCT07125846 — Efficacy of Bioactive Glass vs. Xenograft in Maxillary Sinus Augmentation · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05744622 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Suez Canal University
Last refreshed: 27 February 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05744622.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing